Paulson & Co’s Madrigal Pharmaceuticals MDGL Stock Holding History

Paulson & Co’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$720M	Sell	1,340,020 -52,168	-4%	-$26.7M	27.94%	1
2026 Q1	$729M	Sell	1,392,188 -315,334	-18%	-$151M	23.42%	2
2025 Q4	$994M	Sell	1,707,522 -200,001	-10%	-$102M	30.48%	1
2025 Q3	$875M	Sell	1,907,523 -182,000	-9%	-$67.9M	29.46%	1
2025 Q2	$632M	Sell	2,089,523 -10,000	-0.5%	-$2.98M	31.44%	1
2025 Q1	$695M	Buy	2,099,523 +57,523	+3%	+$18.9M	39.81%	1
2024 Q4	$630M	Hold	2,042,000	–	–	38.14%	1
2024 Q3	$393M	Buy	2,042,000 +192,000	+10%	+$49.1M	27.55%	1
2024 Q2	$518M	Buy	1,850,000 +75,000	+4%	+$17.9M	38.31%	1
2024 Q1	$474M	Buy	1,775,000 +669,259	+61%	+$158M	32.74%	1
2023 Q4	$256M	Buy	1,105,741 +605,741	+121%	+$106M	23.09%	1
2023 Q3	$73M	Buy	500,000 +149,800	+43%	+$28.2M	6.53%	6
2023 Q2	$80.9M	Buy	+350,200	New	+$94.9M	7.9%	5

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Paulson & Co's MDGL Position: Q2 2026 in Review

Paulson & Co reduced its Madrigal Pharmaceuticals (MDGL) stake by 3.7% in Q2 2026, selling an estimated $26.7M and leaving 1,340,020 shares worth $720M. The position accounts for 27.94% of the portfolio, ranked #1.

Paulson & Co first reported a position in MDGL in Q2 2023 and has held it in 13 quarters since. The position peaked at $994M in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Paulson & Co held 1,340,020 shares of Madrigal Pharmaceuticals worth $720M as of Q2 2026.
Paulson & Co sold 52,168 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $26.7M.
Madrigal Pharmaceuticals made up 27.94% of Paulson & Co's portfolio in Q2 2026, its #1 holding.
Paulson & Co first reported a position in Madrigal Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
Paulson & Co's Madrigal Pharmaceuticals position peaked at $994M in Q4 2025.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Paulson & Co's 13F filing for Q2 2026, filed 14 Aug 2026.